Cara Therapeutics (CARA) Gets a Buy Rating from H.C. Wainwright

By Jason Carr

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Cara Therapeutics (CARAResearch Report), with a price target of $30.00. The company’s shares closed last Monday at $18.66.

According to, Livnat is a 4-star analyst with an average return of 10.2% and a 55.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Verrica Pharmaceuticals.

Currently, the analyst consensus on Cara Therapeutics is a Strong Buy with an average price target of $32.67, implying a 57.9% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $35.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.55 and a one-year low of $12.19. Currently, Cara Therapeutics has an average volume of 552.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain.